Meilleure Health International Industry Group Limited (2327) AI Stock Analysis

• Market Cap: HK$1.17B
• Dividend Yield: 0.55%
• Average Volume (3M): 3.52M
• Price to Earnings (P/E): 29.7
• Beta (1Y): 0.37
• Revenue Growth: -54.92%
• EPS Growth: 26.32%
• Country: HK
• Employees: 46
• Sector: Industrials
• Sector Strength: 72
• Industry: Conglomerates
• EPS (TTM): <0.01
• Shares Outstanding: 4,093,756,600
• 10 Day Avg. Volume: 6,054,000
• 30 Day Avg. Volume: 3,517,820
• PEG Ratio: -1.74
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 23.42
• P/FCF Ratio: 6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: HK$0.50 ▲(78.57% Upside)

The overall stock score is primarily influenced by the company's mixed financial performance and technical indicators. The financial performance shows significant volatility, which poses a risk. Technical analysis indicates some short-term positive momentum but lacks strong directional signals. The valuation suggests the stock may be overvalued, further impacting the score.

Meilleure Health International Industry Group Limited Business Overview & Revenue Model

Company Description

Meilleure Health International Industry Group Limited, an investment holding company, engages in industrial hemp, healthcare-related, trading, agency service, property investment and leasing, and property development businesses in Hong Kong, the People's Republic of China, and internationally. The company is involved in the trading of construction materials; development and sale of residential properties; property investment and leasing activities; and sale of healthcare-related products. It also provides real estate agency services; cannabidiol downstream product application services; health management services, including anti-aging, aesthetic medicine, and other health consulting; and healthcare related product sales agency services. The company was formerly known as U-Home Group Holdings Limited and changed its name to Meilleure Health International Industry Group Limited in March 2017. Meilleure Health International Industry Group Limited is headquartered in Admiralty, Hong Kong.

How the Company Makes Money

Meilleure Health International Industry Group Limited generates revenue through the sale of its health and wellness products across various channels, including online platforms, retail stores, and distribution partnerships. The company’s key revenue streams include direct sales of nutritional supplements and health foods, which are complemented by a growing portfolio of personal care items. Additionally, Meilleure Health may engage in partnerships with health-related organizations and retailers to expand its market reach and enhance brand visibility. Factors contributing to its earnings include the increasing global awareness of health and wellness, a rising trend in preventive healthcare, and the growing demand for natural and organic products.

Meilleure Health International Industry Group Limited Financial Statement Overview

Summary

Meilleure Health International Industry Group Limited displays a mixed financial performance with significant volatility across income, balance sheet, and cash flow metrics. While there are periods of profitability and positive cash flow, the inconsistency over the years suggests underlying operational challenges and financial instability.

Income Statement

The company has experienced significant fluctuations in revenue, with a notable decline from 2020 to 2024. Gross profit margin and net profit margin have been inconsistent, indicating volatility in profitability. The EBIT and EBITDA margins have similarly varied, pointing to operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a reasonable level of leverage. However, the equity ratio has been decreasing, which could suggest increasing liabilities relative to assets. Return on equity has been inconsistent, reflecting variability in profitability.

Cash Flow

Cash flow from operations has been unstable, with periods of negative cash flow. Free cash flow growth has been erratic, but the company has managed to maintain positive free cash flow in recent years. The operating cash flow to net income ratio suggests some challenges in translating income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.10M	50.68M	129.30M	119.89M	253.03M	265.13M
Gross Profit	27.67M	28.91M	78.09M	66.76M	100.93M	111.25M
EBITDA	40.49M	56.52M	71.38M	55.46M	108.73M	129.38M
Net Income	39.17M	32.48M	40.83M	17.82M	60.32M	83.44M
Balance Sheet
Total Assets	1.75B	1.67B	1.70B	1.71B	1.74B	1.70B
Cash, Cash Equivalents and Short-Term Investments	9.95M	29.94M	106.31M	210.99M	380.39M	281.28M
Total Debt	345.96M	303.06M	297.06M	249.13M	170.42M	154.84M
Total Liabilities	530.15M	467.29M	442.89M	384.18M	306.35M	299.60M
Stockholders Equity	1.22B	1.20B	1.25B	1.32B	1.43B	1.40B
Cash Flow
Free Cash Flow	60.97M	188.62M	-137.32M	42.10M	-89.79M	70.39M
Operating Cash Flow	61.64M	188.75M	-136.49M	43.15M	-83.27M	70.81M
Investing Cash Flow	-94.72M	-253.98M	53.72M	-134.76M	161.56M	108.14M
Financing Cash Flow	23.96M	-6.39M	-18.90M	41.93M	-38.22M	-108.88M

Meilleure Health International Industry Group Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Neutral. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.28, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.07 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2327.

Meilleure Health International Industry Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8162	72 Outperform	HK$577.27M	11.42	42.14%	―	-11.49%	85.40%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
2327	51 Neutral	HK$1.17B	29.69	3.21%	0.55%	-54.92%	26.32%
0474	48 Neutral	HK$708.65M	-0.77	-191.85%	―	-21.03%	-97.01%
0025	46 Neutral	HK$1.17B	-2.47	-4.99%	4.15%	13.04%	-27.89%
2322	41 Neutral	HK$490.35M	-5.51	-13.05%	―	-49.15%	-1.89%
0925	40 Underperform	―	―	―	―	―	―

Meilleure Health International Industry Group Limited Corporate Events

Meilleure Health Reports Increased Profit Despite Revenue Decline

Meilleure Health International Industry Group Limited announced its unaudited interim results for the six months ending June 30, 2025, reporting a profit of HK$15,144,000, up from HK$8,230,000 in the same period in 2024. Despite a decrease in revenue from HK$30,033,000 to HK$17,453,000, the company managed to increase its profit before tax to HK$15,907,000, attributed to lower costs of goods sold and reduced selling and distribution expenses, indicating improved operational efficiency.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.

Meilleure Health Announces Interim Dividend for 2025

Meilleure Health International Industry Group Limited has announced an interim cash dividend of HKD 0.0015 per share for the six months ended 30 June 2025. The ex-dividend date is set for 24 September 2025, with the record date on 2 October 2025 and payment scheduled for 31 October 2025. This announcement reflects the company’s ongoing commitment to providing returns to its shareholders.

The most recent analyst rating on (HK:2327) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Meilleure Health International Industry Group Limited stock, see the HK:2327 Stock Forecast page.

Meilleure Health Projects Strong Profit Growth for H1 2025

Meilleure Health International Industry Group Limited announced a positive profit alert, expecting a significant increase in profit for the first half of 2025 compared to the same period in 2024. This growth is attributed to increased revenue from property-related business and higher interest income, despite a decrease in healthcare product sales due to challenging conditions in the PRC.

Meilleure Health Schedules Board Meeting to Review Interim Results

Meilleure Health International Industry Group Limited has announced a board meeting scheduled for August 28, 2025, to approve the interim results for the first half of the year and to consider the recommendation of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential returns to shareholders, impacting its market positioning and stakeholder interests.